Mass Oral Azithromycin for Childhood Mortality: Timing of Death After Distribution in the MORDOR Trial | Zendy

Travis C. Porco | Zendy; John Hart | Zendy; Ahmed M. Arzika | Zendy; Jerusha Weaver | Zendy; Khumbo Kalua | Zendy; Zakayo Mrango | Zendy; Sun Y. Cotter | Zendy; Nicole E. Stoller | Zendy; Kieran S. O’Brien | Zendy; Dionna M. Fry | Zendy; Benjamin Vanderschelden | Zendy; Catherine E. Oldenburg | Zendy; Sheila K. West | Zendy; Robin L. Bailey | Zendy; Jeremy D. Keenan | Zendy; Thomas M. Lietman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Mass Oral Azithromycin for Childhood Mortality: Timing of Death After Distribution in the MORDOR Trial

Author(s) -

Travis C. Porco,

John Hart,

Ahmed M. Arzika,

Jerusha Weaver,

Khumbo Kalua,

Zakayo Mrango,

Sun Y. Cotter,

Nicole E. Stoller,

Kieran S. O’Brien,

Dionna M. Fry,

Benjamin Vanderschelden,

Catherine E. Oldenburg,

Sheila K. West,

Robin L. Bailey,

Jeremy D. Keenan,

Thomas M. Lietman

Publication year - 2018

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciy973

Subject(s) - azithromycin , medicine , randomized controlled trial , clinical trial , demography , pediatrics , antibiotics , sociology , microbiology and biotechnology , biology

In a large community-randomized trial, biannual azithromycin distributions significantly reduced postneonatal childhood mortality in sub-Saharan African sites. Here, we present a prespecified secondary analysis showing that much of the protective effect was in the first 3 months postdistribution. Distributing more frequently than biannually could be considered if logistically feasible. Clinical Trials Registration. NCT02047981.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research